1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Shkreli Subpoenaed On Drug Prices, Refuses To Give Up Records

 
• By Donna Young

Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.

Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.

"I have been trying for the better part of a year to get information from Martin Shkreli about his outrageous price increases, and he has obstructed our investigation at every...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.